Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synaptic Transmission Defects Caused by Heterozygous Mutations in NRXN1.

Heterozygous mutations of the NRXN1 gene, which encodes the presynaptic cell-adhesion molecule neurexin-1, were repeatedly associated with autism and schizophrenia. However, diverse clinical presentations of NRXN1 mutations in patients raise the question of whether heterozygous NRXN1 mutations alone directly impair synaptic function. To address this question under conditions that precisely control for genetic background, we generated human ESCs with different heterozygous conditional NRXN1 mutations and analyzed two different types of isogenic control and NRXN1 mutant neurons derived from these ESCs. Both heterozygous NRXN1 mutations selectively impaired neurotransmitter release in human neurons without changing neuronal differentiation or synapse formation. Moreover, both NRXN1 mutations increased the levels of CASK, a critical synaptic scaffolding protein that binds to neurexin-1. Our results show that, unexpectedly, heterozygous inactivation of NRXN1 directly impairs synaptic function in human neurons, and they illustrate the value of this conditional deletion approach for studying the functional effects of disease-associated mutations.

[1]  T. Südhof,et al.  Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin. , 1992, Science.

[2]  Laurent Mottron,et al.  Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia , 2011, Human Genetics.

[3]  K. Kinzler,et al.  Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. , 2004, Nucleic acids research.

[4]  O. Brüstle,et al.  A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration , 2009, Proceedings of the National Academy of Sciences.

[5]  T. Südhof,et al.  Structure and evolution of neurexin genes: insight into the mechanism of alternative splicing. , 2002, Genomics.

[6]  T. Südhof,et al.  Cartography of neurexins: More than 1000 isoforms generated by alternative splicing and expressed in distinct subsets of neurons , 1995, Neuron.

[7]  R. Straub,et al.  Incomplete penetrance of NRXN1 deletions in families with schizophrenia , 2014, Schizophrenia Research.

[8]  J. Doherty,et al.  Recent genomic advances in schizophrenia , 2012, Clinical genetics.

[9]  T. Südhof,et al.  Neurexin III alpha: extensive alternative splicing generates membrane-bound and soluble forms. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Fred H. Gage,et al.  Induced pluripotent stem cells: the new patient? , 2012, Nature Reviews Molecular Cell Biology.

[11]  Wei Xu,et al.  Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development , 2012, Proceedings of the National Academy of Sciences.

[12]  Michael F. Walker,et al.  De novo mutations revealed by whole-exome sequencing are strongly associated with autism , 2012, Nature.

[13]  A. Kaur,et al.  Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. , 2002, Genomics.

[14]  Zhiping P. Pang,et al.  Distinct Neuronal Coding Schemes in Memory Revealed by Selective Erasure of Fast Synchronous Synaptic Transmission , 2012, Neuron.

[15]  E. Banks,et al.  De novo mutations in schizophrenia implicate synaptic networks , 2014, Nature.

[16]  T. Südhof,et al.  Autonomous Function of Synaptotagmin 1 in Triggering Synchronous Release Independent of Asynchronous Release , 2005, Neuron.

[17]  M. Shaw,et al.  CASK mutations are frequent in males and cause X-linked nystagmus and variable XLMR phenotypes , 2010, European Journal of Human Genetics.

[18]  Yiping Shen,et al.  Deletions of NRXN1 (Neurexin-1) Predispose to a Wide Spectrum of Developmental Disorders , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[19]  Eric S. Lander,et al.  A polygenic burden of rare disruptive mutations in schizophrenia , 2014, Nature.

[20]  K. Eggan,et al.  Constructing and Deconstructing Stem Cell Models of Neurological Disease , 2011, Neuron.

[21]  M. State,et al.  Recent developments in the genetics of autism spectrum disorders. , 2013, Current opinion in genetics & development.

[22]  Thomas C. Südhof,et al.  Cartography of neurexin alternative splicing mapped by single-molecule long-read mRNA sequencing , 2014, Proceedings of the National Academy of Sciences.

[23]  Patrick F Sullivan,et al.  The genomics of schizophrenia: update and implications. , 2013, The Journal of clinical investigation.

[24]  W. Regehr Short-term presynaptic plasticity. , 2012, Cold Spring Harbor perspectives in biology.

[25]  Brian E. McIntosh,et al.  Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy , 2011, Proceedings of the National Academy of Sciences.

[26]  Zhiping P. Pang,et al.  Integrative genomic and functional analyses reveal neuronal subtype differentiation bias in human embryonic stem cell lines , 2007, Proceedings of the National Academy of Sciences.

[27]  T. Südhof,et al.  Mouse neurexin-1α deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments , 2009, Proceedings of the National Academy of Sciences.

[28]  T. Südhof,et al.  Calmodulin Suppresses Synaptotagmin-2 Transcription in Cortical Neurons* , 2010, The Journal of Biological Chemistry.

[29]  T. Südhof,et al.  Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem Cells , 2013, Neuron.

[30]  V. Eapen,et al.  Balance within the Neurexin Trans-Synaptic Connexus Stabilizes Behavioral Control , 2014, Front. Hum. Neurosci..

[31]  G. Kirov,et al.  Analysis of copy number variations at 15 schizophrenia-associated loci , 2014, The British journal of psychiatry : the journal of mental science.

[32]  Bradley P. Coe,et al.  Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations , 2012, Nature.

[33]  M. Tomishima,et al.  Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling , 2009, Nature Biotechnology.

[34]  Thomas Vierbuchen,et al.  Induction of human neuronal cells by defined transcription factors , 2011, Nature.

[35]  S. Christian,et al.  Mutations of CASK cause an X-linked brain malformation phenotype with microcephaly and hypoplasia of the brainstem and cerebellum , 2008 .

[36]  T. Südhof,et al.  α-Neurexins couple Ca2+ channels to synaptic vesicle exocytosis , 2003, Nature.

[37]  Marius Wernig,et al.  In vitro differentiation of transplantable neural precursors from human embryonic stem cells , 2001, Nature Biotechnology.

[38]  T. Südhof,et al.  CASK: a novel dlg/PSD95 homolog with an N-terminal calmodulin-dependent protein kinase domain identified by interaction with neurexins , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[39]  Krishanu Saha,et al.  Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues , 2010, Cell.

[40]  J. Lieberman,et al.  Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response , 2010, Human psychopharmacology.

[41]  Prashant Mali,et al.  Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. , 2009, Cell stem cell.

[42]  J. Lieberman,et al.  The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response , 2011, Schizophrenia Research.

[43]  T. Südhof,et al.  Deletion of CASK in mice is lethal and impairs synaptic function , 2007, Proceedings of the National Academy of Sciences.

[44]  Evan T. Geller,et al.  Patterns and rates of exonic de novo mutations in autism spectrum disorders , 2012, Nature.

[45]  T. Südhof Neuroligins and neurexins link synaptic function to cognitive disease , 2008, Nature.

[46]  Christian Rosenmund,et al.  Definition of the Readily Releasable Pool of Vesicles at Hippocampal Synapses , 1996, Neuron.

[47]  S. Antonarakis,et al.  Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature , 2013, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[48]  A. Consiglio,et al.  Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells , 2009, Nature.

[49]  H. Okano,et al.  Modeling human neurological disorders with induced pluripotent stem cells , 2014, Journal of neurochemistry.